Antivirals for Broader Coverage against Human Coronaviruses

Area of Science:

• Virology
• Drug Discovery
• Public Health

Background:

• Coronaviruses (CoVs) are RNA viruses responsible for significant human illness, including the COVID-19 pandemic caused by SARS-CoV-2.
• Seven human CoVs exist, with new zoonotic introductions being inevitable and unpredictable.
• Current treatments like Paxlovid target SARS-CoV-2's main protease, but conserved viral proteomes suggest broader antiviral potential.

Purpose of the Study:

• To identify common features across human coronaviruses for developing broad-spectrum antivirals, biologics, and vaccines.
• To enhance global preparedness for current and future coronavirus outbreaks.
• To reduce the scientific, economic, and public health impact of CoV outbreaks.

Main Methods:

• Review of existing antiviral research targeting coronaviruses.
• Analysis of conserved genetic features among human CoVs.
• Evaluation of current and investigational therapeutic strategies, including antivirals and monoclonal antibodies.

Main Results:

• Approved antivirals like Paxlovid demonstrate potential to inhibit multiple human CoVs, though in vivo efficacy is primarily shown for SARS-CoV-2.
• Investigational drugs show promise for broader CoV targeting but are not yet publicly available.
• Spike protein-targeted vaccines and monoclonal antibodies are less effective for common human CoVs due to sequence variability.

Conclusions:

• There is a critical need for globally accessible treatments targeting all seven human coronaviruses.
• Developing antivirals that target conserved CoV proteomes is essential for future pandemic preparedness.
• A multi-pronged approach combining antivirals, biologics, and vaccines targeting conserved elements is necessary to mitigate the impact of CoV outbreaks.